Palbociclib + Letrozole

DRUG2 trials

Sponsors

Shengjing Hospital, Pfizer

Conditions

Breast CancerMetastatic Breast Cancer

Phase 3

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Shengjing HospitalBreast Cancer

Start: 2019-09-01End: 2022-09-30Target: 420Updated: 2021-07-20

Unknown Phase

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

CompletedNCT04176354

PfizerMetastatic Breast Cancer

Start: 2019-01-25End: 2019-09-27Updated: 2024-08-23

Related Papers

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis

Frontiers in Oncology2022-07-0411 citations

Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis.

2022-05-0520 citations

Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.

2021-08-0223 citations

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.

2021-03-2493 citations